Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Alexander KarachunskiyGesche TallenJulia RoumiantsevaSvetlana LagoikoAlmira ChervovaArend von StackelbergOlga AleinikovaOleg BydanovLyudmila BajdunTatiana NasedkinaNatalia KorepanovaSergei KuznetsovGalina NovichkovaMarina GoroshkovaDmitry LitvinovNatalia MyakovaNatalia PonomarevaEvgeniya InyushkinaKonstantin KondratchikJulia AbugovaLarisa FechinaOleg ArakaevAlexander KarelinVladimir LebedevNatalia JudinaGusel ScharapovaIrina SpichakAnastasia ShamardinaOlga RyskalAlexander ShapochnikAlexander RumjanzewJoachim BoosGünter Henzenull nullPublished in: Journal of cancer research and clinical oncology (2019)
Our findings suggest that weekly 5000 U/m2E. coli-ASP IM during consolidation therapy are equally effective, more cost-efficient and less toxic than 10000 U/m2 for SR patients with childhood ALL.